- ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
- ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
- ChromaDex Corporation Reports First Quarter 2024 Financial Results
- ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
- ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
- ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
- ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
- ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
More ▼
Key statistics
On Friday, Chromadex Corp (CDXC:NAQ) closed at 2.76, 120.80% above the 52 week low of 1.25 set on Oct 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.82 |
---|---|
High | 2.88 |
Low | 2.76 |
Bid | 2.76 |
Offer | 2.90 |
Previous close | 2.83 |
Average volume | 233.23k |
---|---|
Shares outstanding | 75.54m |
Free float | 48.51m |
P/E (TTM) | -- |
Market cap | 208.49m USD |
EPS (TTM) | -0.047 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:15 BST.
More ▼